Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Sofosbuvir/Velpatasvir in Pregnant Women with HCV
NCT04382404Phase 1Completed
- Start
- Oct 2020
- Primary completion
- Oct 2023
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of velpatasvir in hepatitis C (HCV). Primary endpoints: Maximum Concentration of Velpatasvir in Maternal Plasma at 9 weeks, Maximum Concentration of Sofosbuvir in Maternal Plasma at 9 weeks and 4 more. Started Oct 2020; status: completed.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04382404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382404.